These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
54 related articles for article (PubMed ID: 160836)
1. Continuous streptozotocin infusion: a phase I study. Seibert K; Golub G; Smiledge P; Nystrom JS Cancer Treat Rep; 1979; 63(11-12):2035-7. PubMed ID: 160836 [TBL] [Abstract][Full Text] [Related]
2. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas. Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154 [TBL] [Abstract][Full Text] [Related]
3. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology. Early AP; Preisler HD; Slocum H; Rustum YM Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642 [TBL] [Abstract][Full Text] [Related]
4. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion. Egorin MJ; Sigman LM; Van Echo DA; Forrest A; Whitacre MY; Aisner J Cancer Res; 1987 Jan; 47(2):617-23. PubMed ID: 3791246 [TBL] [Abstract][Full Text] [Related]
5. Phase I-II trial of high-dose epirubicin in patients with lymphoma. Case DC; Gams R; Ervin TJ; Boyd MA; Oldham FB Cancer Res; 1987 Dec; 47(23):6393-6. PubMed ID: 3479245 [TBL] [Abstract][Full Text] [Related]
6. Phase II evaluation of cis-dichlorodiammineplatinum(II) in lymphomas: a Southwest Oncology Group Study. Rossof AH; Coltman CA; Jones SE; Talley RW Cancer Treat Rep; 1979; 63(9-10):1605-8. PubMed ID: 498159 [TBL] [Abstract][Full Text] [Related]
7. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells. van Besien K; Margolin K; Champlin R; Forman S Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395 [TBL] [Abstract][Full Text] [Related]
8. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
9. Phase II trial of ifosfamide in children with malignant solid tumors. Pratt CB; Horowitz ME; Meyer WH; Etcubanas E; Thompson EI; Douglass EC; Wilimas JA; Hayes FA; Green AA Cancer Treat Rep; 1987 Feb; 71(2):131-5. PubMed ID: 3100034 [TBL] [Abstract][Full Text] [Related]
10. Phase I trial of pentamethylmelamine in patients with previously treated malignancies. Van Echo DA; Chiuten DF; Whitacre M; Aisner J; Lichtenfeld JL; Wiernik PH Cancer Treat Rep; 1980; 64(12):1335-9. PubMed ID: 6781747 [TBL] [Abstract][Full Text] [Related]
11. Clinical phase I-II study of cis-dichloro-diammineplatinum(II) given by continuous lv infusion. Salem P; Hall SW; Benjamin RS; Murphy WK; Wharton JT; Bodey GP Cancer Treat Rep; 1978 Oct; 62(10):1553-5. PubMed ID: 361227 [TBL] [Abstract][Full Text] [Related]
12. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700 [TBL] [Abstract][Full Text] [Related]
13. Phase I trial of pentamethylmelamine: a clinical and pharmacologic study. Ihde DC; Dutcher JS; Young RC; Cordes RS; Barlock AL; Hubbard SM; Jones RB; Boyd MR Cancer Treat Rep; 1981; 65(9-10):755-62. PubMed ID: 6791819 [TBL] [Abstract][Full Text] [Related]
14. Effect of very high-dose thymidine infusions on leukemia and lymphoma patients. Blumenreich MS; Woodcock TM; Andreeff M; Hiddemann W; Chou TC; Vale K; O'Hehir M; Clarkson BD; Young CW Cancer Res; 1984 May; 44(5):2203-7. PubMed ID: 6713407 [TBL] [Abstract][Full Text] [Related]
15. A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240). Curt GA; Grygiel JJ; Corden BJ; Ozols RF; Weiss RB; Tell DT; Myers CE; Collins JM Cancer Res; 1983 Sep; 43(9):4470-3. PubMed ID: 6347373 [TBL] [Abstract][Full Text] [Related]
16. Clinical phase I-II and pharmacokinetic study of high-dose thymidine given by continuous intravenous infusion. Chiuten DF; Wiernik PH; Zaharko DS; Edwards L Cancer Res; 1980 Mar; 40(3):818-22. PubMed ID: 7471098 [TBL] [Abstract][Full Text] [Related]
17. Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals. Young CW; Fanucchi MP; Declan Walsh T; Baltzer L; Yaldaei S; Stevens YW; Gordon C; Tong W; Rifkind RA; Marks PA Cancer Res; 1988 Dec; 48(24 Pt 1):7304-9. PubMed ID: 3191501 [TBL] [Abstract][Full Text] [Related]
18. Phase I study of YK-176 (2'-deoxycoformycin) in patients with adult T-cell leukemia-lymphoma. The DCF Study Group. Tobinai K; Shimoyama M; Inoue S; Takayasu S; Mikuni C; Kozuru M; Oda S; Nakajima H Jpn J Clin Oncol; 1992 Jun; 22(3):164-71. PubMed ID: 1518164 [TBL] [Abstract][Full Text] [Related]
19. Phase I study of cis-diamminedichloroplatinum(II) administered as a constant 5-day infusion. Lokich JJ Cancer Treat Rep; 1980; 64(8-9):905-8. PubMed ID: 6256073 [TBL] [Abstract][Full Text] [Related]
20. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy. Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]